Immunodominance Among EBV-Derived Epitopes Restricted by HLA-B27 Does Not Correlate with Epitope Abundance in EBV-Transformed B-Lymphoblastoid Cell Lines1
暂无分享,去创建一个
Forest M. White | Jarrod A. Marto | Robert E. Settlage | J. Shabanowitz | D. Hunt | V. Engelhard | F. White | J. Marto | V. Crotzer | A. Rickinson | R. Settlage | Robert E. Christian | J. Brooks | Victor H. Engelhard | Jeffrey Shabanowitz | Alan B. Rickinson | Donald F. Hunt | Victoria L. Crotzer | Jill M. Brooks
[1] S. Carr,et al. Mass Spectrometry in Biology & Medicine , 2000, Humana Press.
[2] C. Herberts,et al. A single naturally processed measles virus peptide fully dominates the HLA‐A*0201‐associated peptide display and is mutated at its anchor position in persistent viral strains , 2000, European journal of immunology.
[3] V. Engelhard,et al. The Density of Peptides Displayed by Dendritic Cells Affects Immune Responses to Human Tyrosinase and gp100 in HLA-A2 Transgenic Mice1 , 2000, The Journal of Immunology.
[4] A. Rickinson,et al. Cytotoxic T-Lymphocyte Responses to a Polymorphic Epstein-Barr Virus Epitope Identify Healthy Carriers with Coresident Viral Strains , 2000, Journal of Virology.
[5] J. Shabanowitz,et al. Sequencing the Primordial Soup , 2000 .
[6] A. Gambotto,et al. Identification of naturally processed and HLA-presented Epstein-Barr virus peptides recognized by CD4(+) or CD8(+) T lymphocytes from human blood. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[7] J. Yewdell,et al. Modification of Cysteine Residues In Vitro and In Vivo Affects the Immunogenicity and Antigenicity of Major Histocompatibility Complex Class I–restricted Viral Determinants , 1999, The Journal of experimental medicine.
[8] S. Rowland-Jones,et al. A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers. , 1999, Journal of immunology.
[9] A. Rickinson,et al. HLA-B27 subtype polymorphism and CTL epitope choice: studies with EBV peptides link immunogenicity with stability of the B27:peptide complex. , 1998, Journal of immunology.
[10] R. Zinkernagel,et al. Comparison of activation versus induction of unresponsiveness of virus-specific CD4+ and CD8+ T cells upon acute versus persistent viral infection. , 1998, Immunity.
[11] H. Rammensee,et al. Protective Immunity Does Not Correlate with the Hierarchy of Virus-specific Cytotoxic T Cell Responses to Naturally Processed Peptides , 1998, The Journal of experimental medicine.
[12] A. Rickinson,et al. Relationship between peptide binding and T cell epitope selection: a study with subtypes of HLA-B27. , 1998, International immunology.
[13] P. Cresswell,et al. Mechanisms of MHC class I--restricted antigen processing. , 1998, Annual review of immunology.
[14] P. Paz,et al. Minors held by majors: the H13 minor histocompatibility locus defined as a peptide/MHC class I complex. , 1997, Immunity.
[15] D. Busch,et al. MHC class I antigen processing of Listeria monocytogenes proteins: implications for dominant and subdominant CTL responses , 1997, Immunological reviews.
[16] E. Pamer,et al. Immunodominant and subdominant CTL responses to Listeria monocytogenes infection. , 1997, Journal of immunology.
[17] D. Moss,et al. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. , 1997, Annual review of immunology.
[18] J. Yewdell,et al. MHC class I-associated peptides produced from endogenous gene products with vastly different efficiencies. , 1997, Journal of immunology.
[19] A. Agulnik,et al. The HLA-A*0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition. , 1997, Immunity.
[20] Alan G. Marshall,et al. Stored waveform inverse Fourier transform (SWIFT) ion excitation in trapped-ion mass spectometry: Theory and applications , 1996 .
[21] N. Shastri,et al. Alloreactive CD8+ T cells can recognize unusual, rare, and unique processed peptide/MHC complexes. , 1996, Journal of immunology.
[22] J. Albar,et al. Binding of peptides naturally presented by HLA-B27 to the differentially disease-associated B*2704 and B*2706 subtypes, and to mutants mimicking their polymorphism. , 1996, Tissue antigens.
[23] C. Rice,et al. Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients , 1996, Journal of virology.
[24] G. Cooper,et al. Frequency of multiple Epstein-Barr virus infections in T-cell-immunocompromised individuals , 1996, Journal of virology.
[25] H. Eisen,et al. Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response. , 1996, Immunity.
[26] J. Berzofsky,et al. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[27] A. Abbas,et al. The roles of costimulation and Fas in T cell apoptosis and peripheral tolerance. , 1996, Immunity.
[28] V. Levitsky,et al. The life span of major histocompatibility complex-peptide complexes influences the efficiency of presentation and immunogenicity of two class I-restricted cytotoxic T lymphocyte epitopes in the Epstein-Barr virus nuclear antigen 4 , 1996, The Journal of experimental medicine.
[29] J. Shabanowitz,et al. An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins , 1996, The Journal of experimental medicine.
[30] R. J. Cohen,et al. The law of mass action governs antigen-stimulated cytolytic activity of CD8+ cytotoxic T lymphocytes. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[31] R. Anderson,et al. Antigen processing in vivo and the elicitation of primary CTL responses. , 1995, Journal of immunology.
[32] B. Moss,et al. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis , 1995, The Journal of experimental medicine.
[33] H. Eisen,et al. Variations in the number of peptide-MHC class I complexes required to activate cytotoxic T cell responses. , 1995, Journal of immunology.
[34] R C Brower,et al. Minimal requirements for peptide mediated activation of CD8+ CTL. , 1994, Molecular immunology.
[35] L. Young,et al. Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state , 1994, Journal of virology.
[36] R. Young,et al. Naturally processed viral peptides recognized by cytotoxic T lymphocytes on cells chronically infected by human immunodeficiency virus type 1 , 1994, The Journal of experimental medicine.
[37] R. Zinkernagel,et al. T-cell-mediated immunopathology versus direct cytolysis by virus: implications for HIV and AIDS. , 1994, Immunology today.
[38] P. Cresswell,et al. Association of human class I MHC alleles with the adenovirus E3/19K protein. , 1994, Journal of immunology.
[39] A Sette,et al. Naturally processed peptides longer than nine amino acid residues bind to the class I MHC molecule HLA-A2.1 with high affinity and in different conformations. , 1994, Journal of immunology.
[40] R. Zinkernagel,et al. Peripheral clonal deletion of antiviral memory CD8+ T cells , 1993, European journal of immunology.
[41] A. Rickinson,et al. Different HLA-B27 subtypes present the same immunodominant Epstein-Barr virus peptide , 1993, The Journal of experimental medicine.
[42] X. Jin,et al. Quantitative analysis of the human immunodeficiency virus type 1 (HIV- 1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein- Barr virus in late disease , 1993, The Journal of experimental medicine.
[43] Rolf M. Zinkernagel,et al. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells , 1993, Nature.
[44] R. Henderson,et al. Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. , 1992, Science.
[45] D. R. Madden,et al. Identification of self peptides bound to purified HLA-B27 , 1991, Nature.
[46] U. Nater,et al. Epstein-Barr virus. , 1991, The Journal of family practice.
[47] S. Burrows,et al. Cytotoxic T-cell clones discriminate between A- and B-type Epstein-Barr virus transformants , 1988, Nature.
[48] N. Raab-Traub,et al. Epstein-Barr virus replication in oropharyngeal epithelial cells. , 1984, The New England journal of medicine.
[49] M. Epstein,et al. Epstein–Barr virus-specific cytotoxic T-cell clones restricted through a single HLA antigen , 1982, Nature.